Abstracts tagged "Malignancy"

Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Takuma Tsuzuki Wada¹, Yuji Akiyama¹ and Toshihide Mimura², ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…
Abstract Number: 1694 • 2015 ACR/ARHP Annual Meeting
All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J. Mease¹, Alice B. Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Describe characteristics and incidence rates of all-cause mortality and malignancies (excluding NMSC) in psoriasis pts with psoriatic arthritis (PsA) from PSOLAR. Methods: PSOLAR is…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2141 • 2015 ACR/ARHP Annual Meeting
Risk of Cancer in Non-TNFi Biologics-Treated RA
Hjalmar Wadström¹, Johan Askling² and the ARTIS study group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute…
Abstract Number: 2664 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Hematological Malignancies in Children Born to Women with SLE
Evelyne Vinet¹, Ann E. Clarke², Christian A. Pineau³, Susan Scott⁴, Robert W. Platt⁵ and Sasha Bernatsky⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose Patients with SLE have an increased risk of hematological malignancies, particularly non-Hodgkin lymphoma, compared to the general population. Recently, in utero exposures, such as…
Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
David Fiorentino¹, Mark Lebwohl², Vincent Ho³, Richard Langley⁴, Kavitha Goyal⁵, Steve Fakharzadeh⁶, Steve Calabro⁵ and Wayne Langholff⁷, ¹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Mount Sinai Medical Center, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Services, LLC, Spring House, PA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…
Abstract Number: 1265 • 2014 ACR/ARHP Annual Meeting
Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase
Pari Basharat¹, Arash Lahouti H.¹, Andrew L. Mammen², Iago Pinal-Fernandez¹, Tanmayee Bichile³, Thomas E. Lloyd⁴, Sonye K. Danoff⁵, Livia Casciola-Rosen⁶ and Lisa Christopher-Stine⁷, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ³Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Neurology, Johns Hopkins, Baltimore, MD, ⁵Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ⁶Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose The idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune disorders that target skeletal muscle. Some IIM cases may be associated with an autoantibody…
Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Jeffrey R. Curtis¹, E.B. Lee², G. Martin³, X. Mariette⁴, K.K. Terry⁵, Y. Chen⁶, J. Geier⁷, J. Andrews⁵, M. Kaur⁶, K. Kwok⁷ and C. Nduaka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Seoul National University College of Medicine, Seoul, South Korea, ³Dermatology and Laser Center of Maui, Kihei, HI, ⁴Paris-Sud University, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…
Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
Abstract Number: 585 • 2013 ACR/ARHP Annual Meeting
Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁵, Christine Peschken⁶, William Foulkes¹, Yvan St. Pierre⁷, Patrice Chrétien Raymer⁷, Basile Tessier Cloutier⁸, Guillermo Ruiz-Irastorza⁹, Ann E. Clarke¹ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁰, ¹McGill University, Montreal, QC, Canada, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁸Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹⁰(coordinating centre), Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: There is an increase in cancer in SLE over-all, but decrease in other cancers, such as breast cancer. Of particular interest are autoantibodies targeting…
Abstract Number: 419 • 2013 ACR/ARHP Annual Meeting
A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Yukiko Kamogawa¹, Kyohei Nakamura², Ryu Watanabe², Tsuyoshi Shirai¹, Yoko Fujita³, Yuko Shirota⁴, Noriko Fukuhara¹, Hiroshi Fujii², Shinichiro Saito⁵, Tomonori Ishii² and Hideo Harigae², ¹Tohoku University, Sendai, Japan, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁴Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of hematology and rheumatology, Tohoku University, Sendai, Japan
Background/Purpose: Methotrexate (MTX) has been increasingly administered by patients with rheumatoid arthritis (RA). In rare cases, we experience development of malignant lymphoma in patients treated…
Abstract Number: 2901 • 2013 ACR/ARHP Annual Meeting
Standardized Incidence Ratios For Cancer After Renal Transplant In Systemic Lupus Erythematosus and Non-Systemic Lupus Erythematosus Recipients
Rosalind Ramsey-Goldman¹, Amarpali Brar², Moro Salifu², Ann E. Clarke³, Rahul M. Jindal⁴ and Sasha Bernatsky³, ¹Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, SUNY Downstate, Brooklyn, NY, ³McGill University, Montreal, QC, Canada, ⁴Surgery, Uniformed Services University and George Washington University, Washington, DC
Background/Purpose: Differentiating between effects of drugs vs. disease activity on cancer risk in SLE is difficult. Because all renal transplant recipients are on similar immunomodulatory…
Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Ronald F. van Vollenhoven¹, Andrea Rubbert-Roth², Anthony Sebba³, Benjamin Porter-Brown⁴, Lucy Rowell⁵, Pavel Napalkov⁶ and Devi Smart⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Med Clinic I, University of Cologne, koln, Germany, ³University of South Florida, Tampa, FL, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Epidemiology, Genentech, South San Francisco, CA
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
Abstract Number: 1037 • 2013 ACR/ARHP Annual Meeting
Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Atsushi Hashimoto¹, Noriyuki Chiba², Jinju Nishino³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].